Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate
Recruitment status was: Recruiting
Hypothesis: Treatment with Glatiramer acetate prevents deterioration of gait in multiple sclerosis (MS) patients.
During the study patients will undergo a 3 dimensional gait analysis before starting treatment with glatiramer acetate and after 1 year of treatment.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Three Dimensional Gait Evaluation in Relapsing Remitting Multiple Sclerosis Patients Treated With Glatiramer Acetate|
- Computerized gait analysis: at the beginning of treatment and after 1 year
|Study Start Date:||May 2006|
Patients with a definite diagnosis of relapsing remitting multiple sclerosis (MS) will undergo a 3 dimensional gait analysis before initiation of treatment with glatiramer acetate. The gait analysis will include kinematic evaluation using a Charnwood Dynamics CODA CX-1 system, 4 AMTI force plates and a Noraxon telemetric EMG system. Patients will be videotaped and will also undergo a detailed physical examination by a physical therapist.
Treatment with Glatiramer acetate will be initiated after the gait analysis. Therapy will be observed and controlled by a neurologist fromn the staff of the Multiple Sclerosis Center.
Repeat gait analysis will be performed after one year of treatment.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00331747
|Multiple Sclerosis Center, Sheba Medical Center|
|Tel Hashomer, Israel, 52621|
|Principal Investigator:||Uri Givon, MD||Sheba Medical Center; Tel Aviv University|
|Study Chair:||Anat Achiron, MD, PhD||Sheba Medical Center; Tel Aviv University|